News

The biocatalysis technology is a greener, cleaner, and more economic way to manufacture chiral drugs cutting the production costs by 25-30%. The company has wound up the plans

The new formula, which increases macular pigment density through all-natural ingredients, includes 10mg of dietary Zeaxanthin and 10mg of Lutein. ZeaVision president Chris Barber said macular pigment plays

Rivastigmine is generic equivalent to Novartis’ Exelon capsules. Rivastigmine is indicated for use in the symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson’s

The open-label dose-escalating trial evaluated toxicity and efficacy of perifosine, given in monotherapy to patients with neuroblastoma. Aeterna Zentaris president and CEO Juergen Engel said the data emphasise

The diabetes drug candidate successfully completed Phase 2 development in 2010. Novo Nordisk executive vice president and chief science officer Mads Thomsen said semaglutide represents to further improve

The agreement will initially focus on multiple clinical trial programs in oncology. Bristol-Myers global development and medical affairs senior vice president Brian Daniels said the partnership is aligned

The patent applications concern its proprietary formulation technologies for its products TX12001HR, TX12002HR and TX12003HR. TherapeuticsMD CEO Robert Finizio said, "The submission of these patents marks a new

The FDA approval is based on two randomized trials which showed that Lyrica significantly reduced neuropathic pain associated with spinal cord injury from baseline throughout the duration of

The Olanzapine and Fluoxetine Capsules are the company’s generic equivalent to Symbyax. Lilly USA commercializes Symbyax, which is approved for the acute treatment of treatment-resistant depression and bipolar